Skip to content

Study · Randomized controlled trial · n = 1,176 · 2015

3 results

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet A, Andersen JR, Riis BJ, Bay-Jensen AC, Christiansen C

Osteoarthritis and cartilage9 Jan 2015Cited by 109 (Europe PMC)

PMID25582279 (opens in a new tab)DOI10.1016/j.joca.2014.12.019 (opens in a new tab)PepBankPUB-25582279
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In CSMC021C2301, oral sCT with 5-CNAC carrier did not significantly affect joint space narrowing versus placebo.

    In plain wordsIn CSMC021C2301, oral sCT with 5-CNAC carrier did not significantly affect joint space narrowing versus placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeJoint space narrowing in CSMC021C2301
    Study

    n = 1,176

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.8 mg twice daily · oral · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 24 month endpoint there was no statistically significant treatment effect on joint space narrowing (JSN) in any of the two studies.
    2 context sentences
    Summary · context
    This is the combined reporting of two randomized, double-blind, multi-center, placebo-controlled trials (CSMC021C2301 and CSMC021C2302), evaluating the efficacy and safety of oral sCT in patients with painful knee OA with structural manifestations, enrolling 1176 and 1030 patients, respectively.
    Summary · context
    Study subjects were randomized (1:1) to oral sCT 0.8 mg twice daily or placebo (PBO) for 24 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In CSMC021C2302, oral sCT with 5-CNAC carrier did not significantly affect joint space narrowing versus placebo.

    In plain wordsIn CSMC021C2302, oral sCT with 5-CNAC carrier did not significantly affect joint space narrowing versus placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeJoint space narrowing in CSMC021C2302
    Study

    n = 1,030

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.8 mg twice daily · oral · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 24 month endpoint there was no statistically significant treatment effect on joint space narrowing (JSN) in any of the two studies.
    2 context sentences
    Summary · context
    This is the combined reporting of two randomized, double-blind, multi-center, placebo-controlled trials (CSMC021C2301 and CSMC021C2302), evaluating the efficacy and safety of oral sCT in patients with painful knee OA with structural manifestations, enrolling 1176 and 1030 patients, respectively.
    Summary · context
    Study subjects were randomized (1:1) to oral sCT 0.8 mg twice daily or placebo (PBO) for 24 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In CSMC021C2301, oral sCT with 5-CNAC affected WOMAC scores and bone and joint biomarkers versus placebo. Hierarchical testing prevented statistical significance claims.

    In plain wordsIn CSMC021C2301, oral sCT with 5-CNAC affected WOMAC scores and bone and joint biomarkers versus placebo. Hierarchical testing prevented statistical significance claims.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedWOMAC scores and bone and joint metabolism biomarkers in CSMC021C2301
    Study

    n = 1,176

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.8 mg twice daily · oral · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    In CSMC021C2301 there was a treatment effect on WOMAC (sum of pain, function, stiffness, and total scores) as well as on the biomarkers of bone and joint metabolism, but due to the hierarchical testing procedure the treatment effect was not claimed statistically significant.
    1 context sentence
    Summary · context
    Study subjects were randomized (1:1) to oral sCT 0.8 mg twice daily or placebo (PBO) for 24 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 3Results postedNCT00704847

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

Nordic Bioscience A/Sn = 1,030Jun 2008 to Jun 2011

Osteoarthritis

Trial pageClinicalTrials.govUpdated 24 Apr 2019
CompletedPhase 3Results postedNCT00486434

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis

Nordic Bioscience A/Sn = 1,176May 2007 to Sept 2010

Osteoarthritis

Trial pageClinicalTrials.govUpdated 26 Apr 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.